Old Web
English
Sign In
Acemap
>
authorDetail
>
Ivo Sonderegger
Ivo Sonderegger
Boehringer Ingelheim
Biosimilar
Medicine
Adalimumab
Immunogenicity
Bioequivalence
5
Papers
113
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
2018
Steven Ramael
Benjamin Van Hoorick
Renger Tiessen
Thijs van Iersel
Viktoria Moschetti
Benjamin Lang
Ivo Sonderegger
Sabrina Wiebe
Bernd Liedert
Girish Jayadeva
Show All
Source
Cite
Save
Citations (8)
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
2018
Annals of the Rheumatic Diseases
Stanley Cohen
Alberto Alonso Ruiz
Piotr Adrian Klimiuk
Eric Lee
Nuala Peter
Ivo Sonderegger
Deepak Assudani
Show All
Source
Cite
Save
Citations (65)
AB0391 Similar pharmacokinetics, safety and tolerability of the adalimumab biosimilar candidate BI 695501 administered subcutaneously via prefilled syringe (PFS) or autoinjector (AI) (voltaire®-ai)
2017
Annals of the Rheumatic Diseases
Steven Ramael
Viktoria Moschetti
Nuala Peter
Ivo Sonderegger
Sabrina Wiebe
B Liedert
Show All
Source
Cite
Save
Citations (0)
FRI0189 Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire®-ra)
2017
Annals of the Rheumatic Diseases
Stanley Cohen
A Alonso Ruiz
Piotr Adrian Klimiuk
Eric Lee
Nuala Peter
Ivo Sonderegger
Deepak Assudani
Show All
Source
Cite
Save
Citations (6)
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects
2016
Expert Opinion on Investigational Drugs
Christopher Wynne
Mario Altendorfer
Ivo Sonderegger
Lien Gheyle
. Rod Ellis-Pegler
Susanne Buschke
Benjamin Lang
Deepak Assudani
Sandeep Athalye
Niklas Czeloth
Show All
Source
Cite
Save
Citations (34)
1